Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016

  • ID: 3788890
  • Drug Pipelines
  • 107 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Argos Therapeutics, Inc.
  • e-Therapeutics Plc
  • F. Hoffmann-La Roche Ltd.
  • Invectys SA
  • Johnson & Johnson
  • Ultimovacs AS
  • MORE
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016

Summary

‘Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Review, H1 2016’, provides in depth analysis on Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted pipeline therapeutics.

The report provides comprehensive information on the Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49)
- The report reviews Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics and enlists all their major and minor projects
- The report assesses Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Argos Therapeutics, Inc.
  • e-Therapeutics Plc
  • F. Hoffmann-La Roche Ltd.
  • Invectys SA
  • Johnson & Johnson
  • Ultimovacs AS
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Overview

Therapeutics Development

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Stage of Development

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Therapy Area

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Indication

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Unknown Stage Products

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Companies

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Products under Development by Universities/Institutes

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Companies Involved in Therapeutics Development

Adamis Pharmaceuticals Corporation

Argos Therapeutics, Inc.

Asterias Biotherapeutics, Inc.

e-Therapeutics Plc

F. Hoffmann-La Roche Ltd.

Inovio Pharmaceuticals, Inc.

Invectys SA

Johnson & Johnson

Komipharm International Co., Ltd.

Mediolanum farmaceutici S.p.A.

Ultimovacs AS

Vaxon Biotech

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Drug Profiles

ASTVAC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASTVAC-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETS-2300 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Alzheimer’s Disease and Atherosclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GX-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

imetelstat sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-1400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INO-5400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INVAC-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KML-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rocapuldencel-T - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Telomerase for Lung Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate Telomerase for ALS, GVHD, Ageing and Leukemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TeloB-VAX - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tertomotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UCPVax - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UV-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Telomerase for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Telomerase for Solid Tumor - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-016 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vbx-026 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vx-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vx-006 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Dormant Projects

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Discontinued Products

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) - Featured News & Press Releases

Jun 13, 2016: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 in Metastatic Renal Cell Carcinoma Following Interim Data Review

May 02, 2016: Asterias Biotherapeutics Announces Oral Presentation at ASGCT 19th Annual Meeting

Apr 20, 2016: Geron Announces Two Imetelstat Poster Presentations at the American Association for Cancer Research Annual Meeting

Mar 23, 2016: Argos Therapeutics Announces Initiation of a Phase 2 Clinical Trial of AGS-003 for the Treatment of Non-small Cell Lung Cancer in Combination with Standard-of-Care Chemotherapy

Mar 02, 2016: New trial launched to test cancer vaccine

Feb 24, 2016: Asterias Biotherapeutics Announces Successful End-of-Phase 2 Meeting with FDA for AST-VAC1

Jan 21, 2016: Asterias Biotherapeutics Announces Completion of Transfer of AST-VAC2 Manufacturing Process to Cancer Research UK as Milestone Towards Initiating Phase 1/2 Clinical Trial

Jan 14, 2016: Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes

Dec 10, 2015: Independent Data Monitoring Committee Recommends Continuation of ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma Following Second Planned Interim Analysis

Nov 05, 2015: Geron Announces Presentations at American Society of Hematology Annual Meeting

Nov 05, 2015: Janssen to Present Posters on Imetelstat at the 2015 American Society of Hematology Annual Meeting

Oct 30, 2015: Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine

Sep 16, 2015: Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis

Sep 02, 2015: Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of Imetelstat in Hematologic Myeloid Malignancies

Aug 10, 2015: Argos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer 107List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Number of Products under Investigation by Universities/Institutes, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by Adamis Pharmaceuticals Corporation, H1 2016

Pipeline by Argos Therapeutics, Inc., H1 2016

Pipeline by Asterias Biotherapeutics, Inc., H1 2016

Pipeline by e-Therapeutics Plc, H1 2016

Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Pipeline by Inovio Pharmaceuticals, Inc., H1 2016

Pipeline by Invectys SA, H1 2016

Pipeline by Johnson & Johnson, H1 2016

Pipeline by Komipharm International Co., Ltd., H1 2016

Pipeline by Mediolanum farmaceutici S.p.A., H1 2016

Pipeline by Ultimovacs AS, H1 2016

Pipeline by Vaxon Biotech, H1 2016

Dormant Projects, H1 2016

Dormant Projects (Contd..1), H1 2016

Dormant Projects (Contd..2), H1 2016

Dormant Projects (Contd..3), H1 2016

Discontinued Products, H1 2016

Discontinued Products (Contd..1), H1 2016

Discontinued Products (Contd..2), H1 2016

Discontinued Products (Contd..3), H1 2016 91List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Argos Therapeutics, Inc.
  • e-Therapeutics Plc
  • F. Hoffmann-La Roche Ltd.
  • Invectys SA
  • Johnson & Johnson
  • Ultimovacs AS
  • MORE
Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) Telomerase reverse transcriptase is a catalytic subunit of the enzyme telomerase. Telomerase activity is regulated by a number of factors including telomerase complex-associated proteins, chaperones and polypeptide modifiers. It modulates Wnt signaling. It plays important role in aging and antiapoptosis.

Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) pipeline Target constitutes close to 25 molecules. Out of which approximately 21 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 6, 3, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 2 molecules, respectively.

Our latest report Telomerase Reverse Transcriptase – Pipeline Review, H1 2016, outlays comprehensive information on the Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Telomerase Reverse Transcriptase (Telomerase or HEST2 or Telomerase Catalytic Subunit or Telomerase-Associated Protein 2 or EC 2.7.7.49) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Adamis Pharmaceuticals Corporation
Argos Therapeutics, Inc.
Asterias Biotherapeutics, Inc.
e-Therapeutics Plc
F. Hoffmann-La Roche Ltd.
Inovio Pharmaceuticals, Inc.
Invectys SA
Johnson & Johnson
Komipharm International Co., Ltd.
Mediolanum farmaceutici S.p.A.
Ultimovacs AS
Vaxon Biotech
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll